Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? (original) (raw)

References

  1. Hilleman, M.R. Six decades of vaccine development—a personal history. Nature Med. 4, 507—514 ( 1998).
    Article CAS Google Scholar
  2. Edelson, B.T., Cossart, P. & Unanue, E.R. Paradigm revisited: antibody provides resistance to Listeria infection. J. Immunol. 163, 4087 –4090 (1999).
    CAS Google Scholar
  3. Casadevall, A. Antibody-mediated protection against intracellular pathogens. Trends Microbiol. 6, 102–107 (1998).
    Article CAS Google Scholar
  4. Kostrikis, L.G., Cao, Y., Ngai, H., Moore, J.P. & Ho, D.D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70, 445–458 ( 1996).
    CAS Google Scholar
  5. Moore, J.P. et al. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70, 427–444 ( 1996).
    CAS Google Scholar
  6. Moog, C., Fleury, H.J.A., Pellegrin, I., Kirn, A. & Aubertin, A.M. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71, 3734–3741 (1997).
    CAS Google Scholar
  7. Gauduin, M.-C. et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Med. 3, 1389–1393 (1997).
    Article CAS Google Scholar
  8. Mascola, J.R. et al. Protection of macaques against pathogenic SHIV-89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–4018 (1999).
    CAS Google Scholar
  9. Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian/human immunodeficiency virus infection. Nature Med. 6, 200–206 ( 2000).
    Article CAS Google Scholar
  10. Mascola, J.R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6, 207–210 ( 2000).
    Article CAS Google Scholar
  11. Sanchez, A. et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72, 6442– 6447 (1998).
    CAS Google Scholar
  12. Maruyama, T. et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol 73, 6024–6030 (1999).
    CAS Google Scholar
  13. Connolly, B.M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179, (supplement 1 ), 5201–5217 (1999).
    Google Scholar
  14. Roben, P. et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821–4828 (1994).
    CAS Google Scholar
  15. Sattentau, Q.J. & Moore, J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182, 185– 196 (1995).
    Article CAS Google Scholar
  16. Fouts, T.R., Binley, J.M., Trkola, A., Robinson, J.E. & Moore, J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex . J. Virol. 71, 2779–2785 (1997).
    CAS Google Scholar
  17. Parren, P.W.H.I. et al. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity . J. Virol. 72, 3512–3519 (1998).
    CAS Google Scholar
  18. Wrin, T. et al. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 7, 211–219 (1994).
    CAS Google Scholar
  19. Nyambi, P.N. et al. Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIV cpz-ant . J. Virol. 71, 2320– 2330 (1997).
    CAS Google Scholar
  20. Murphy, B.R. & Webster, R. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 1397–1446 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996).
    Google Scholar
  21. Kwong, P.D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648–659 ( 1998).
    Article CAS Google Scholar
  22. Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein . Nature 393, 705–711 (1998).
    Article CAS Google Scholar
  23. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888 (1998).
    Article CAS Google Scholar
  24. Griffin, D. E. & Bellini, W. J. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 1267– 1312 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996).
    Google Scholar
  25. Wolinsky, J.S. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 899–930 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996).
    Google Scholar
  26. Binley, J.M. et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74, 627– 643 (2000).
  27. Reitter, J.N., Means, R.E. & Desrosiers, R.C. A role for carbohydrates in immune evasion in AIDS . Nature Med. 4, 679–684 (1998).
    Article CAS Google Scholar
  28. Patten, P.A., Howard, R.J. & Stemmer, W.P. Applications of DNA shuffling to pharmaceuticals and vaccines. Curr. Opin. Biotechnol. 8, 724 –733 (1997).
    Article CAS Google Scholar
  29. Dempsey, P.W., Allison, M.E.D., Akkaraju, S., Goodnow, C.C. & Fearon, D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348–350 (1996).
    Article CAS Google Scholar
  30. Barber, B.H. The immunotargeting approach to adjuvant-independent subunit vaccine design . Sem. Immunol. 9, 293– 301 (1997).
    Article CAS Google Scholar
  31. Wang, H., Griffiths, M.N., Burton, D.R. & Ghazal, P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc. Natl. Acad. Sci. USA (in the press).
  32. Steward, M.W., Stanley, C.M. & Obeid, O.E. A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response. J. Virol. 69, 7668–7673 (1995).
    CAS Google Scholar
  33. Chargelegue, D. et al. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo. J. Virol. 72, 2040–2046 (1998).
    CAS Google Scholar
  34. Puntoriero, G. et al. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J. 17, 3521–3533 (1998).
    Article CAS Google Scholar
  35. Mulligan, M.J. & Weber, J. Human trials of HIV-1 vaccines. AIDS 13, S105– S112 (1999).
    CAS Google Scholar

Download references